A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
出版年份 2016 全文链接
标题
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
作者
关键词
-
出版物
BRITISH JOURNAL OF DERMATOLOGY
Volume 174, Issue 6, Pages 1266-1276
出版商
Wiley
发表日期
2016-01-22
DOI
10.1111/bjd.14403
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
- (2014) Edward C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
- (2013) B. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment
- (2012) Sonia A. Lamel et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
- (2012) Rosa Parisi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
- (2012) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
- (2009) Mary G. Boy et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started